Role of two efflux proteins, ABCB1 and ABCG2, in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 12, Issue 2, 2009, Pages 199-208

  Vautier, Sarah ^a   Milane, Aline ^a   Fernandez, Christine ^a,b   Bourasset, Fanchon ^a   Chacun, Hélène ^a   Lacomblez, Lucette ^b   Farinottti, Robert ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BREAST CANCER RESISTANCE PROTEIN; BROMOCRIPTINE; INULIN; MULTIDRUG RESISTANCE PROTEIN 1; SUCROSE; ABC TRANSPORTER; ABCB1 PROTEIN, MOUSE; ABCG2 PROTEIN, MOUSE; ANTIPARKINSON AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN CAPILLARY; BRAIN PERFUSION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TRANSPORT; MOUSE; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; INTOXICATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METABOLISM; PATHOPHYSIOLOGY; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL; WESTERN BLOTTING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPARKINSON AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN; BROMOCRIPTINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; PARKINSON DISEASE; TISSUE DISTRIBUTION;

EID: 70349309511     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J3B596     Document Type: Article

References (48)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 5:525-35, 2006
2. Heikkila RE, Nicklas WJ, Vyas I, Duvoisin RC. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci Lett 62:389-94, 1985
3. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107-10, 1968
4. Langston JW, Langston EB, Irwin I. MPTPinduced parkinsonism in human and nonhuman primates--clinical and experimental aspects. Acta Neurol Scand Suppl 100:49-54, 1984
5. Tipton KF, Singer TP. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191-206, 1993
6. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-62, 1976
7. Soares-Da-Silva P, Serrao MP. Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells. J Pharmacol Exp Ther 293:697-704, 2000
8. Soares-da-Silva P, Serrao MP, Vieira-Coelho MA, Pestana M. Evidence for the involvement of P-glycoprotein on the extrusion of taken up L-DOPA in cyclosporine A treated LLC-PK1 cells. Br J Pharmacol 123:13-22, 1998
9. Denora N, Laquintana V, Lopedota A, Serra M, Dazzi L, Biggio G, Pal D, Mitra AK, Latrofa A, Trapani G, Liso G. Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety. Pharm Res 24:1309-24, 2007
10. Vautier S, Lacomblez L, Chacun H, Picard V, Gimenez F, Farinotti R, Fernandez C. Interactions between the dopamine agonist, bromocriptine and the efflux protein, Pglycoprotein at the blood-brain barrier in the mouse. Eur J Pharm Sci 27:167-74, 2006
11. Orlowski S, Valente D, Garrigos M, Ezan E. Bromocriptine modulates P-glycoprotein function. Biochem Biophys Res Commun 244:481-8, 1998
12. Shiraki N, Okamura K, Tokunaga J, Ohmura T, Yasuda K, Kawaguchi T, Hamada A, Nakano M. Bromocriptine reverses Pglycoprotein-mediated multidrug resistance in tumor cells. Jpn J Cancer Res 93:209-15, 2002
13. Uhr M, Ebinger M, Rosenhagen MC, Grauer MT. The anti-Parkinson drug budipine is exported actively out of the brain by Pglycoprotein in mice. Neurosci Lett 383:73-6, 2005
14. Buyse M, Radeva G, Bado A, Farinotti R. Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol 69:1745-54, 2005
15. Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol 13:463-9, 2001
16. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42:1501-6, 2001
17. Merino V, Jimenez-Torres NV, Merino-Sanjuan M. Relevance of multidrug resistance proteins on the clinical efficacy of cancer therapy. Curr Drug Deliv 1:203-12, 2004
18. Lee G, Bendayan R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res 21:1313-30, 2004
19. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, Snyder J, Zhu YG, Ling ZD. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. Eur J Neurosci 22:1158-68, 2005
20. Rousselet E, Joubert C, Callebert J, Parain K, Tremblay L, Orieux G, Launay JM, Cohen-Salmon C, Hirsch EC. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol Dis 14:218-28, 2003
21. Lau YS, Novikova L, Roels C. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact. Neurosci Res 52:371-8, 2005
22. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Schinkel AH. Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier Pglycoprotein by oral treatment of mice with PSC833. J Clin Invest 100:2430-6, 1997
23. Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J Cereb Blood Flow Metab 20:381-6, 2000
24. Cattelotte J, Andre P, Ouellet M, Bourasset F, Scherrmann JM, Cisternino S. In situ mouse carotid perfusion model: glucose and cholesterol transport in the eye and brain. J Cereb Blood Flow Metab 2008
25. Song S, Suzuki H, Kawai R, Sugiyama Y. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab Dispos 27:689-94, 1999
26. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P. Absence of the mdr1a PGlycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-705, 1995
27. Triguero D, Buciak J, Pardridge WM. Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins. J Neurochem 54:1882-8, 1990
28. Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 235:H299-307, 1978
29. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57:173-85, 2005
30. Thumwood CM, Hunt NH, Clark IA, Cowden WB. Breakdown of the blood-brain barrier in murine cerebral malaria. Parasitology 96 (Pt 3):579-89, 1988
31. Hommes OR, Obbens EA, Wijffels CC. Epileptogenic activity of sodium-folate and the blood-brain barrier in the rat. J Neurol Sci 19:63-71, 1973
32. Hermsen CC, Mommers E, van de Wiel T, Sauerwein RW, Eling WM. Convulsions due to increased permeability of the blood-brain barrier in experimental cerebral malaria can be prevented by splenectomy or anti-T cell treatment. J Infect Dis 178:1225-7, 1998
33. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22:1763-71, 2002
34. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. Faseb J 16:1474-6, 2002
35. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74:2213-6, 2000
36. Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL. COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 14:1927-9, 2003
37. Muramatsu Y, Kurosaki R, Watanabe H, Michimata M, Matsubara M, Imai Y, Araki T. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study. J Neural Transm 110:1129-44, 2003
38. Guerin CJ, Nolan CC, Mavroudis G, Lister T, Davidson GM, Holton JL, Ray DE. The dynamics of blood-brain barrier breakdown in an experimental model of glial cell degeneration. Neuroscience 103:873-83, 2001
39. Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets 6:295-311, 2006
40. Combates NJ, Rzepka RW, Chen YN, Cohen D. NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol Chem 269:29715-9, 1994
41. Bauer B, Hartz AM, Fricker G, Miller DS. Pregnane X receptor up-regulation of Pglycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 66:413-9, 2004
42. Regina A, Romero IA, Greenwood J, Adamson P, Bourre JM, Couraud PO, Roux F. Dexamethasone regulation of Pglycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. J Neurochem 73:1954-63, 1999
43. Mandi Y, Ocsovszki I, Szabo D, Nagy Z, Nelson J, Molnar J. Nitric oxide production and MDR expression by human brain endothelial cells. Anticancer Res 18:3049-52, 1998
44. Zhao YL, Du J, Kanazawa H, Cen XB, Takagi K, Kitaichi K, Tatsumi Y, Ohta M, Hasegawa T. Shiga-like toxin II modifies brain distribution of a P-glycoprotein substrate, doxorubicin, and P-glycoprotein expression in mice. Brain Res 956:246-53, 2002
45. Staal RG, Yang JM, Hait WN, Sonsalla PK. Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 910:116-25, 2001
46. Xia CQ, Yang JJ, Gan LS. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 1:595-611, 2005
47. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-92, 2002
48. Gao B, Stieger B, Noe B, Fritschy JM, Meier PJ. Localization of the organic anion transporting polypeptide 2 (Oatp2) in capillary endothelium and choroid plexus epithelium of rat brain. J Histochem Cytochem 47:1255-64, 1999